May 20, 2021 11:13 AM EDT
News Briefing

Bio­Th­eryX col­lects $92M in Se­ries E round; WuXi Bi­o­log­ics ups its stake in an emerg­ing ADC play­er

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Bio­Th­eryX is con­tin­u­ing to rake in in­vestor cap­i­tal, net­ting a fresh $92 mil­lion Se­ries E round on Thurs­day.

The San Diego …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

A look at biotech's year of the megaround

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Eli Lil­ly seeks to join law­suit over end of tirzepatide short­age

A service from the Financial Times